NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
9.91
Dollar change
-0.81
Percentage change
-7.56
%
Index- P/E- EPS (ttm)-0.90 Insider Own54.01% Shs Outstand11.13M Perf Week26.56%
Market Cap110.54M Forward P/E6.31 EPS next Y1.57 Insider Trans0.00% Shs Float5.13M Perf Month28.53%
Enterprise Value107.86M PEG- EPS next Q-0.17 Inst Own3.01% Short Float2.43% Perf Quarter71.75%
Income-9.97M P/S46.06 EPS this Y43.43% Inst Trans36.85% Short Ratio1.55 Perf Half Y137.08%
Sales2.40M P/B21.61 EPS next Y380.36% ROA-93.62% Short Interest0.12M Perf YTD110.40%
Book/sh0.46 P/C37.34 EPS next 5Y- ROE-108.02% 52W High11.78 -15.87% Perf Year65.44%
Cash/sh0.27 P/FCF- EPS past 3/5Y-7.15% -18.10% ROIC-190.80% 52W Low3.72 166.23% Perf 3Y304.25%
Dividend Est.- EV/EBITDA- Sales past 3/5Y14.58% 41.99% Gross Margin32.88% Volatility12.28% 8.30% Perf 5Y-69.32%
Dividend TTM- EV/Sales44.94 EPS Y/Y TTM-17.30% Oper. Margin-259.07% ATR (14)0.77 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.47 Sales Y/Y TTM18.92% Profit Margin-415.83% RSI (14)69.95 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.71 EPS Q/Q39.77% SMA2024.47% Beta1.28 Target Price15.00
Payout- Debt/Eq0.05 Sales Q/Q63.37% SMA5045.17% Rel Volume2.24 Prev Close10.72
Employees- LT Debt/Eq0.02 EarningsJul 02 SMA20062.77% Avg Volume80.59K Price9.91
IPONov 30, 2017 Option/ShortNo / Yes EPS/Sales Surpr.0.00% 0.00% Trades Volume180,813 Change-7.56%
Date Action Analyst Rating Change Price Target Change
Jan-22-25Initiated Noble Capital Markets Outperform $13
Jul-02-25 08:05AM
Jul-01-25 07:00AM
Jun-18-25 07:00AM
Jun-09-25 07:30AM
Jun-03-25 08:00AM
08:00AM Loading…
Jun-02-25 08:00AM
May-30-25 05:20PM
May-27-25 08:00AM
Apr-30-25 07:30AM
Apr-11-25 07:00AM
Apr-04-25 05:41PM
07:00AM
Feb-21-25 07:00AM
Feb-13-25 07:00AM
Feb-11-25 09:00AM
08:45AM Loading…
Feb-07-25 08:45AM
Dec-31-24 07:00AM
Dec-28-24 09:30AM
Dec-27-24 09:25AM
Dec-04-24 09:00AM
07:00AM
Nov-27-24 07:00AM
Oct-31-24 08:35AM
Oct-17-24 07:00AM
Oct-02-24 07:00AM
Sep-24-24 08:45AM
07:00AM
Sep-20-24 06:50AM
Sep-16-24 04:00PM
Sep-04-24 07:00AM
07:00AM Loading…
Jul-19-24 07:00AM
Jul-15-24 07:00AM
Jun-25-24 06:52AM
Jun-20-24 07:00AM
Jun-03-24 07:00AM
May-21-24 07:00AM
May-16-24 07:00AM
May-10-24 09:00AM
May-03-24 11:54AM
Apr-25-24 07:00AM
Apr-24-24 07:00AM
Apr-23-24 07:00AM
Apr-19-24 07:00AM
Apr-01-24 07:00AM
Mar-27-24 05:50AM
Mar-25-24 07:00AM
Mar-04-24 07:00AM
Jan-29-24 07:00AM
Jan-26-24 07:00AM
Jan-05-24 09:15AM
Dec-18-23 11:52AM
Nov-28-23 07:00AM
Nov-08-23 07:00AM
Oct-11-23 07:42AM
Sep-20-23 09:15AM
07:30AM
Sep-12-23 07:00AM
Sep-11-23 07:00AM
Aug-30-23 08:00AM
Jul-27-23 08:30AM
Jul-14-23 09:20AM
Jun-23-23 07:00AM
May-10-23 08:00AM
Apr-29-23 08:13AM
Apr-27-23 08:00AM
Apr-24-23 09:00AM
Apr-19-23 07:00AM
Apr-04-23 07:00AM
Mar-28-23 08:00AM
Mar-08-23 08:00AM
Mar-02-23 08:00AM
Feb-15-23 06:00AM
Jan-24-23 06:00AM
Jan-05-23 06:00AM
Dec-30-22 06:30AM
Dec-29-22 06:30AM
Dec-14-22 07:00AM
06:00AM
Dec-05-22 07:00AM
Dec-03-22 07:50AM
Dec-02-22 07:00AM
Dec-01-22 07:00AM
Nov-08-22 07:00AM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-17-22 07:00AM
Oct-04-22 07:00AM
Oct-03-22 08:10AM
07:00AM
Sep-15-22 08:00AM
Sep-08-22 07:00AM
Aug-16-22 06:00AM
Aug-10-22 06:00AM
Aug-01-22 06:00AM
Jul-28-22 08:45AM
Jul-27-22 06:00AM
Jul-26-22 06:00AM
Jul-22-22 07:00AM
Jul-21-22 09:00AM
Jul-15-22 07:00AM
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It operates through the Pocono Pharmaceuticals and 4P Therapeutics segments. The Pocono Pharmaceuticals segment relates to a coated products manufacturing entity. The 4P Therapeutics segment performs contract research and development services. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2012 and is headquartered in Orlando, FL.